We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Expanding Diabetes Business Supports ABT Stock, FX Issues Stay
Read MoreHide Full Article
Abbott’s (ABT - Free Report) diversified business portfolio is well-positioned to drive continued momentum in 2025. Yet, the international business environment continues to be challenging. The stock carries a Zacks Rank #3 (Hold).
Factors Driving ABT Shares
Within Abbott’s Established Pharmaceuticals Division (EPD) business, the company is strategically progressing in biosimilars. Abbott, leveraging on its leading presence in emerging markets, is enjoying a unique opportunity to scale a licensing model that is capital-efficient and can bring access to these life-changing medicines to the emerging market population. The first round of commercialization is on track for 2025. The company is highly optimistic about this initiative, considering the fact that biosimilars represent the highest growth segment in the branded generic pharmaceutical market.
Abbott continues to expand its Diagnostics business (comprised 23% of the total revenues in the fourth quarter of 2024). Over the past few quarters, the company has been witnessing increased global demand for routine diagnostics (excluding COVID-19 testing sales). In the fourth quarter of 2024, rapid diagnostics, excluding COVID-testing sales, increased 16% year over year. Core Laboratory Diagnostics’ growth of 4% was driven by continued strong demand for Abbott’s immunoassay, clinical chemistry, hematology and blood screening testing panels.
Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose monitoring (CGM) systems for both Type 1 and Type 2 users.
In the fourth quarter, in Diabetes Care, sales of CGM exceeded $1.8 billion and grew 23%. For full-year 2024, sales of CGM were approximately $6.5 billion and grew 22% from 2023. This included growth of 27% in the United States.
Over the past three months, shares of ABT have gained 11.8% compared with the industry’s 6.2% growth. The company’s consistent efforts to expand in the high-growth areas, as well as its array of new product launches, are expected to help maintain the stock’s uptrend in the coming days.
Concerns Remain for Abbott
Foreign exchange is a major headwind for Abbott due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company’s performance in the international markets. In the fourth quarter of 2024, foreign exchange had an unfavorable year-over-year impact of 1.4% on sales.
The challenging macroeconomic scenario in the form of the ongoing complex geo-political situation globally, specifically where Abbott operates, is driving a higher-than-anticipated increase in expenses in terms of raw materials and freight. These could also result in broader economic impacts and security concerns, affecting the company’s business in the upcoming months. Industrywide, it has been seen that the deteriorating global economic environment is reducing demand for several MedTech products, resulting in lower sales and lower product prices while increasing the cost of goods and operating expenses of the businesses of the MedTech companies.
In the fourth quarter, Abbott incurred an 8.5% increase in the cost of products sold (excluding amortization expense). The gross margin contracted 55 basis points to 55%. Selling, general and administration expenses were up 6.7% year over year, resulting in a 43-basis point contraction in adjusted operating margin.
VCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. Veracyte’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.
ResMed, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 21.1% for 2025. RMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.41%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year.
Omnicell, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 72.7% for fourth-quarter 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 121.74%. OMCL’s shares have risen 26.4% against the industry’s 15.7% decline in the past year.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Expanding Diabetes Business Supports ABT Stock, FX Issues Stay
Abbott’s (ABT - Free Report) diversified business portfolio is well-positioned to drive continued momentum in 2025. Yet, the international business environment continues to be challenging. The stock carries a Zacks Rank #3 (Hold).
Factors Driving ABT Shares
Within Abbott’s Established Pharmaceuticals Division (EPD) business, the company is strategically progressing in biosimilars. Abbott, leveraging on its leading presence in emerging markets, is enjoying a unique opportunity to scale a licensing model that is capital-efficient and can bring access to these life-changing medicines to the emerging market population. The first round of commercialization is on track for 2025. The company is highly optimistic about this initiative, considering the fact that biosimilars represent the highest growth segment in the branded generic pharmaceutical market.
Abbott continues to expand its Diagnostics business (comprised 23% of the total revenues in the fourth quarter of 2024). Over the past few quarters, the company has been witnessing increased global demand for routine diagnostics (excluding COVID-19 testing sales). In the fourth quarter of 2024, rapid diagnostics, excluding COVID-testing sales, increased 16% year over year. Core Laboratory Diagnostics’ growth of 4% was driven by continued strong demand for Abbott’s immunoassay, clinical chemistry, hematology and blood screening testing panels.
Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose monitoring (CGM) systems for both Type 1 and Type 2 users.
In the fourth quarter, in Diabetes Care, sales of CGM exceeded $1.8 billion and grew 23%. For full-year 2024, sales of CGM were approximately $6.5 billion and grew 22% from 2023. This included growth of 27% in the United States.
Abbott Laboratories Price
Abbott Laboratories price | Abbott Laboratories Quote
Over the past three months, shares of ABT have gained 11.8% compared with the industry’s 6.2% growth. The company’s consistent efforts to expand in the high-growth areas, as well as its array of new product launches, are expected to help maintain the stock’s uptrend in the coming days.
Concerns Remain for Abbott
Foreign exchange is a major headwind for Abbott due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company’s performance in the international markets. In the fourth quarter of 2024, foreign exchange had an unfavorable year-over-year impact of 1.4% on sales.
The challenging macroeconomic scenario in the form of the ongoing complex geo-political situation globally, specifically where Abbott operates, is driving a higher-than-anticipated increase in expenses in terms of raw materials and freight. These could also result in broader economic impacts and security concerns, affecting the company’s business in the upcoming months. Industrywide, it has been seen that the deteriorating global economic environment is reducing demand for several MedTech products, resulting in lower sales and lower product prices while increasing the cost of goods and operating expenses of the businesses of the MedTech companies.
In the fourth quarter, Abbott incurred an 8.5% increase in the cost of products sold (excluding amortization expense). The gross margin contracted 55 basis points to 55%. Selling, general and administration expenses were up 6.7% year over year, resulting in a 43-basis point contraction in adjusted operating margin.
Key Picks
Some better-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , ResMed (RMD - Free Report) and Omnicell (OMCL - Free Report) .
Veracyte, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated earnings growth rate of 65.8% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. Veracyte’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.
ResMed, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 21.1% for 2025. RMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.41%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year.
Omnicell, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 72.7% for fourth-quarter 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 121.74%. OMCL’s shares have risen 26.4% against the industry’s 15.7% decline in the past year.